Indeed, it has revealed that therapies such as ipilimumab and pembrolizumab which target the CTLA4 and PD-1 immune checkpoints, respectively, have raised the 3 years survival of patients with melanoma to 70%, and overall survival (>5 years) to 30% in phase III clinical trials (90). Here, CTLA4 is linked to melanoma.